What is the role of hydroxyzine (Vistaril/Atarax) in anxiety management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydroxyzine for Anxiety Management

Hydroxyzine is NOT recommended as a first-line treatment for anxiety disorders and should not be used as a substitute for evidence-based therapies like SSRIs, SNRIs, or cognitive behavioral therapy. 1, 2

Evidence Base and Limitations

The evidence supporting hydroxyzine for anxiety is weak and outdated:

  • A 2010 Cochrane systematic review found hydroxyzine more effective than placebo for generalized anxiety disorder, BUT concluded it cannot be recommended as a reliable first-line treatment due to high risk of bias in included studies, small sample sizes, and limited number of trials. 3

  • The most recent controlled trials supporting hydroxyzine efficacy date from the 1990s, showing benefit at 50 mg daily for GAD with early cognitive symptom improvement. 4, 5 However, these studies predate modern anxiety treatment guidelines that prioritize SSRIs and SNRIs.

  • Current major anxiety treatment guidelines (American Academy of Child and Adolescent Psychiatry 2020, Japanese Society 2023) do not include hydroxyzine as a recommended treatment option, focusing instead on SSRIs and SNRIs as first-line pharmacotherapy. 1

Specific Clinical Concerns

Lack of Evidence for Specific Populations

  • The American Academy of Child and Adolescent Psychiatry explicitly states that hydroxyzine lacks evidence for treating anger, irritability, or mood instability in adolescents and should NOT be used as a substitute for adequate antidepressant dosing when depression is present. 2

Cognitive and Safety Issues

  • Hydroxyzine causes CNS impairment, delirium, and sedation, particularly in older adults due to anticholinergic effects. 2 The Mayo Clinic rates this evidence as moderate strength.

  • Recent 2025 data shows hydroxyzine is now the most identified antihistamine in impaired driving investigations, associated with incoordination, slurred speech, erratic driving, and crashes. 6 Mean blood concentrations in these cases were 70 ng/mL.

  • The American Academy of Allergy, Asthma, and Immunology notes that first-generation antihistamines like hydroxyzine are associated with cognitive decline, particularly with long-term use and in elderly populations. 7

Drug Interaction Considerations

  • Hydroxyzine must be stopped 7-10 days before oral food challenge testing due to antihistamine properties. 2

  • The American Academy of Child and Adolescent Psychiatry recommends avoiding combining hydroxyzine with other anticholinergic medications to prevent cumulative effects. 7

When Hydroxyzine Might Be Considered (Limited Role)

If hydroxyzine is used despite limited evidence, specific parameters apply:

  • For benzodiazepine withdrawal support: One 1997 study showed hydroxyzine 50 mg reduced withdrawal symptoms and anxiety during lorazepam discontinuation, though no significant difference from placebo was found. 5

  • Dosing: 50 mg daily showed more consistent benefit than 25 mg in older trials. 4, 5

  • Duration: Should be shortest possible to minimize anticholinergic burden and cognitive effects. 7

  • Monitoring: Watch for daytime sleepiness (more frequent at 50 mg), sedation, and cognitive impairment. 5, 6

Preferred Evidence-Based Alternatives

SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline) and SNRIs (venlafaxine, duloxetine) are the recommended first-line pharmacological treatments for anxiety disorders in both adults and children/adolescents 6-18 years old, with high-quality evidence showing improvement in anxiety symptoms, treatment response, remission, and global function. 1

  • SSRIs show moderate to high strength of evidence with NNT = 4.70 for treatment response. 1

  • SNRIs show similar efficacy with NNT = 4.94. 1

  • Both classes have similar dropout rates to placebo, indicating acceptable tolerability. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hydroxyzine's Clinical Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Hydroxyzine for generalised anxiety disorder.

The Cochrane database of systematic reviews, 2010

Research

Recent clinical trials of hydroxyzine in generalized anxiety disorder.

Acta psychiatrica Scandinavica. Supplementum, 1998

Research

Hydroxyzine in Impaired Driving Investigations.

Journal of analytical toxicology, 2025

Guideline

Hydroxyzine and Cognitive Effects in Younger Populations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.